Share Fillip As Indian Pharma Crests US Regulatory Hump
This article was originally published in PharmAsia News
Executive Summary
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.